MobiHealth News September 26, 2019
23andMe, a frontrunner in the consumer genomics space, is turning its attention to clinical trial recruitment. The company has inked a deal with TrialSpark, a health tech platform that lets providers become clinical trial sites, connecting their customers to the latter’s trial network.
The new deal will use 23andMe’s crowdsourced research platform, which lets its customers opt into research and supply their non-genetic information. The consumer genomics company is then able to identify and contact patients likely to be appropriate for specific clinical trials.
“23andMe’s unique model solves for the biggest challenge in clinical trials — patient recruitment,” Emily Drabant Conley, VP of business development at 23andMe, said in a statement. “It’s game changing, because it is built...